leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 15:15:47 - browse：398

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Overprescribed: High cost isn't America's only drug problem

WSS

https://cbu01.alicdn.com/img/ibank/2017/877/136/4527631778_1721053343.220x220xz.jpg

The high personal cost of affirmative action for Black doctors

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

First Opinion on colorectal cancer screening: letter and response

The high personal cost of affirmative action for Black doctors

leisure time

leisure time

knowledge

How to save PrEP access — and even expand it

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Wildfire smoke exposes gaps in outdoor worker protections

‘Oppenheimer’ and the risks of AI in health care

Medicare details structure of new drug price negotiation program

The high personal cost of affirmative action for Black doctors

Dobbs anniversary: the lost opportunity of abortion as health care

Scientists uncover potential path to treating deadly childhood tumor

New air purifier tech could be key to improving indoor air quality

Medicare Advantage 2025 payments will dip, Biden administration says

leisure time

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Scientists uncover potential path to treating deadly childhood tumor

Trump indictment: Who are the 'co

Bird flu in dairy cattle: New measures to control spread to humans

Mega Millions pot grows to $1.25 billion after no winner

NIH launches clinical trials and new research office for long Covid

knowledge

focus

explore

knowledge